Cigna Corporation (CI) Holdings Held by Oak Associates Ltd. OH
Oak Associates Ltd. OH held its position in Cigna Corporation (NYSE:CI) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,000 shares of the health services provider’s stock at the end of the 2nd quarter. Oak Associates Ltd. OH’s holdings in Cigna Corporation were worth $2,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. American Beacon Advisors Inc. bought a new stake in Cigna Corporation in the 1st quarter valued at about $102,000. Capstone Investment Advisors Netherlands B.V. bought a new stake in Cigna Corporation in the 2nd quarter valued at about $106,000. Parallel Advisors LLC boosted its holdings in Cigna Corporation by 62.3% in the 2nd quarter. Parallel Advisors LLC now owns 800 shares of the health services provider’s stock valued at $139,000 after purchasing an additional 307 shares during the period. Guardian Life Insurance Co. of America boosted its holdings in Cigna Corporation by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 990 shares of the health services provider’s stock valued at $145,000 after purchasing an additional 7 shares during the period. Finally, Acrospire Investment Management LLC boosted its holdings in Cigna Corporation by 66.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the health services provider’s stock valued at $167,000 after purchasing an additional 400 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.
Cigna Corporation (CI) traded down 0.66% during trading on Monday, reaching $184.92. 408,677 shares of the company were exchanged. The firm’s 50-day moving average is $185.32 and its 200 day moving average is $170.46. Cigna Corporation has a one year low of $115.03 and a one year high of $193.00. The company has a market capitalization of $46.56 billion, a P/E ratio of 21.34 and a beta of 0.43.
Cigna Corporation (NYSE:CI) last announced its earnings results on Friday, August 4th. The health services provider reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.48 by $0.43. The business had revenue of $10.32 billion for the quarter, compared to the consensus estimate of $10.26 billion. Cigna Corporation had a net margin of 5.55% and a return on equity of 17.40%. Cigna Corporation’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $1.98 earnings per share. On average, analysts anticipate that Cigna Corporation will post $10.03 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/cigna-corporation-ci-holdings-held-by-oak-associates-ltd-oh/1634798.html.
In related news, insider Matthew G. Manders sold 24,357 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $175.01, for a total value of $4,262,718.57. Following the sale, the insider now directly owns 46,256 shares of the company’s stock, valued at $8,095,262.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mary T. Hoeltzel sold 525 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $177.59, for a total transaction of $93,234.75. Following the completion of the sale, the vice president now directly owns 1,924 shares in the company, valued at $341,683.16. The disclosure for this sale can be found here. Insiders sold 70,653 shares of company stock worth $12,437,684 over the last ninety days. 1.30% of the stock is currently owned by insiders.
A number of analysts have issued reports on the stock. UBS AG reissued a “buy” rating and issued a $193.00 price objective (up previously from $186.00) on shares of Cigna Corporation in a report on Thursday, June 22nd. Royal Bank Of Canada restated a “buy” rating and issued a $185.00 target price on shares of Cigna Corporation in a research report on Wednesday, August 9th. Deutsche Bank AG boosted their target price on shares of Cigna Corporation from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, August 7th. Zacks Investment Research cut shares of Cigna Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Citigroup Inc. boosted their target price on shares of Cigna Corporation from $185.00 to $198.00 and gave the company a “buy” rating in a research report on Monday, August 7th. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $192.33.
Cigna Corporation Company Profile
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corporation (NYSE:CI).
Receive News & Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.